# Association between Plateletcrit and Preeclampsia

Thesis

Submitted for partial fulfillment of Master Degree in Obstetrics and Gynecology

By

#### **Hovey Mohammed Sabry**

M.B.B., CH – Zagazig University – 2009

Under Supervision of

#### **Prof. Magdy Mohammed Kamal**

Professor of Obstetrics and Gynecology, Faculty of Medicine, Ain Shams University

#### Assist. Prof. Adel Shafik Salah El-Din

Assistant professor of Obstetrics and Gynecology, Faculty of Medicine, Ain Shams University

> Faculty of Medicine Ain Shams University 2018



سورة البقرة الآية: ٣٢

#### Acknowledgment

First and foremost, I feel always indebted to AUAH, the

Most Kind and Most Merciful.

I'd like to express my respectful thanks and profound gratitude to **Prof. Dr. Magdy**Mohammed Kamal, Professor of Obstetrics and Gynecology, Faculty of Medicine, Ain Shams University for his keen guidance, kind supervision, valuable advice and continuous encouragement, which made possible the completion of this work.

I am also delighted to express my deepest gratitude and thanks to Assist. Prof. Adel Shafik Salah El-Din, Assistant professor of Obstetrics and Gynecology, Faculty of Medicine, Ain Shams University, for his kind care, continuous supervision, valuable instructions, constant help and great assistance through out this work.

I would like to express my hearty thanks to all my family for their support till this work was completed.

Last but not least my sincere thanks and appreciation to all patients participated in this study.

Hovey Mohammed Sabry

### List of Contents

Title	Page No.
List of Tables	
List of Figures	ii
List of Abbreviations	
Protocol	
Introduction	
Review of Literature	
<ul> <li>Platelet Physiology</li> </ul>	5
<ul> <li>Preeclampsia Error! Bookn</li> </ul>	nark not defined.
Patients and Methods60	
Results	
Discussion9	
Summary	117
Conclusion	119
References1	
Arabic Summary	

# List of Tables

Table No	. Title	Page No.
Table (1):	Platelet indices	17
<b>Table (2):</b>	Major risk factors for pre-eclampsia	29
<b>Table (3):</b>	Therapeutic agents for control of severe hyper	tension
	in pregnancy	56
<b>Table (4):</b>	Difference between Groups reg	garding
	Demographic Data	
<b>Table (5):</b>	Blood Pressure and Serum Albumin in	Both
	Groups	78
<b>Table (6):</b>	Difference between Groups regarding	g Hb
	Concentration, Serum Chemistry and INR	80
<b>Table (7):</b>	Difference between Groups regarding Platelet	
<b>Table (8):</b>	Difference between Women with Mild P	
	Women with Severe PE regarding Platelet In	
<b>Table (9):</b>	Validity of the Association between I	
	Indices and Diagnosis of PE	
<b>Table (10):</b>	Validity of the Association between I	
	Indices and Diagnosis of Severe PE	92

### List of Figures

Fig. No.	Title Page	No.
Figure (1):	The multifunctional platelet	7
Figure (2):	Platelet-activation mechanisms and role of the	
	P2Y12 receptor	
Figure (3):	Failure of physiological transformation of the spiral	
	arteries is implicated in pre-eclampsia	
Figure (4):	Aspects of pathophysiology of pre-eclampsia	46
Figure (5):	Integrated model of the complex pathophysiology	
	of pre-eclampsia	
Figure (6):	Management of pre-eclampsia	
Figure (7):	Algorithm for antihypertensive treatment of pre-	
	eclampsia	57
Figure (8):	Box-and-Whisker Plot Chart showing Difference	
	between Groups regarding Age	
Figure (9):	Box-and-Whisker Plot Chart showing Difference	
	between Groups regarding Parity	
Figure (10):	Pie-Chart showing Difference between Groups	
	regarding Parity	
Figure (11):	Box-and-Whisker Plot Chart showing Difference	
	between Groups regarding Gestational Age	77
<b>Figure (12):</b>	Box-and-Whisker Plot Chart showing Systolic	<b>7</b> 0
F1 (44)	Blood Pressure in Women of Both Groups	78
Figure (13):	Box-and-Whisker Plot Chart showing Diastolic	<b>7</b> 0
F: (4.4)	Blood Pressure in Women of Both Groups	79
Figure (14):	Box-and-Whisker Plot Chart showing Serum	70
F: (15)	Albumin in Women of Group I	/9
Figure (15):	Box-and-Whisker Plot Chart showing Difference	0.1
E: (10).	between Groups regarding Hb Concentration	81
Figure (16):	Box-and-Whisker Plot Chart showing Difference	01
Figure (17).	between Groups regarding BUN	81
Figure (17):	Box-and-Whisker Plot Chart showing Difference	02
Figure (10).	between Groups regarding Serum Creatinine	82
<b>Figure (18):</b>	Box-and-Whisker Plot Chart showing Difference	02
Figure (10):	between Groups regarding Serum AST Box-and-Whisker Plot Chart showing Difference	02
<b>Figure (19):</b>	between Groups regarding Serum ATT	83

## List of Figures (Cont.)

Fig. No.	Title Page N	<b>V</b> o.
<b>Figure (20):</b>	Box-and-Whisker Plot Chart showing Difference	
	between Groups regarding INR	83
<b>Figure (21):</b>	Box-and-Whisker Plot Chart showing Difference	
	between Groups regarding Platelet Count	85
<b>Figure (22):</b>	Box-and-Whisker Plot Chart showing Difference	
	between Groups regarding MPV	85
<b>Figure (23):</b>	Box-and-Whisker Plot Chart showing Difference	
	between Groups regarding PDW	86
<b>Figure (24):</b>	Box-and-Whisker Plot Chart showing Difference	
	between Groups regarding Plateletcrit	86
<b>Figure (25):</b>	Box-and-Whisker Plot Chart showing Difference	
	between Women with Mild PE and Women with	
	Severe PE regarding Platelet Count	88
<b>Figure (26):</b>	Box-and-Whisker Plot Chart showing Difference	
	between Women with Mild PE and Women with	
	Severe PE regarding MPV	88
<b>Figure (27):</b>	Box-and-Whisker Plot Chart showing Difference	
	between Women with Mild PE and Women with	
	Severe PE regarding PDW	89
<b>Figure (28):</b>	Box-and-Whisker Plot Chart showing Difference	
	between Women with Mild PE and Women with	
	Severe PE regarding Plateletcrit	89
Figure (29 a	& b): ROC Curves for the Association between	
•	Platelet Indices and Diagnosis of PE	90
<b>Figure (30):</b>	ROC Curves for the Association between Platelet	
	Indices and Diagnosis of Severe PE	92

### List of Abbreviations

Abb.	Full term
ADP	Adenosine 5∂-diphosphate
ALT	Alanine aminotransferase
AST	Aspartate aminotransferase
AT1	Type-1 angiotensin II receptor
ATP	Adenosine 5- triphosphate
BUN	Blood urea nitrogen
CBC	Complete blood count
CI	Confidence interval
CTG	Cardio topography
CV	Cardiovascular
DBP	Diastolic blood pressure
DM	Diabetes mellitus
ER	Endoplasmic reticulum
FHR	Fetal heart rate
F1	Femtoliters
Hb	Hemoglobin
INR	International normalized ratio
IPF	Immature platelet fraction
ITP	Immune thrombocytopenia
IUGR	Intrauterine growth restriction
KIRs	Killer cell immunoglobulin-like receptors
MBP	Mean blood pressure
MPC	Mean platelet component
MPM	Mean platelet mass

#### List of Abbreviations (Cont.)

Abb.	Full term
MPV	. Mean platelets volume
OCS	. Open canalicular system
OR	. Odds ratio
PCDW	. Platelet component distribution width
PCT	. Plateletcrit
PDW	. Platelets distributed width
PE	. Preeclampsia
Pg	. Picogram
PI	. Platelet indices
P-LCR	. Platelet larger cell ratio
PlGF	. Placental growth factor
RR	. Relative risk
SBP	. Systolic blood pressure
SPSS	. Statistical Package for the Social Sciences
sVEGFR-1	. Soluble vascular endothelial growth factor receptor 1
TGF-03	. Transforming growth factor 🛮 3
VEGF	. Vascular endothelial growth factor

#### Introduction

Preeclampsia (PE) is a multifactorial disease, characterized by the presence of high blood pressure and proteinuria after the 20th week of pregnancy. PE occurs in 5–8% of pregnancies worldwide and is an important cause of maternal and fetal death. Its prevalence varies in different populations and in different ethnic groups (*Trogstad et al., 2011*).

Diagnosis is made primarily based on blood pressure measurement and determination of the proteinuria and clinical data (Yang et al., 2014).

It is classified into mild and severe preeclampsia according to severity of symptoms:

- Severe PE was diagnosed using the following: a blood pressure elevation with a systolic blood pressure of ≥ 160 mm Hg or a diastolic blood pressure of ≥110 mm Hg and proteinuria >3+ on a urine dipstick.
- For the diagnosis of mild PE, a systolic blood pressure between 140 and 160 mmHg and a diastolic blood pressure between 90 and 110 mmHg, and proteinuria >1+ or 2+ on a urine dipstick was considered significant. A minimum of two consecutive positive measurements was required for the diagnosis (*Freitas et al.*, 2013).

Preeclampsia is one of the most important causes of maternal and fetal morbidity and mortality. Many theories are proposed for the pathophysiology of pre-eclampsia. The formation of a utero placental vasculature insufficient to supply adequate blood to the developing fetus results in fetoplacental hypoxia, leading to imbalances in the release and metabolism of prostaglandins, endothelin and nitric oxide by placental and extra placental tissues. As well as enhanced lipid peroxidation and other undefined factors contribute to the hypertension, platelet activation and systemic endothelial dysfunction characteristics of preeclampsia. Activation of coagulation system in small vessels and increased platelet aggregation is present in preeclampsia. It is clear that preeclampsia is one of the causes of maternal thrombocytopenia and the platelet count increases rapidly after the delivery. There are studies suggesting the storage of platelet in the areas with endothelial damage as the cause of thrombocytopenia. The platelet counts were lower, while the mean platelet volume, platelet distribution width and platelet large cell ratio were increased in preeclampsia as compared to control group (Annam et al., *2011*).

Platelets are anuclear cell fragments derived from the cytoplasm of bone marrow megakaryocytes that circulate in the blood stream of humans for 7-10 days. The function of platelets is to prevent excess bleeding and also play an important role in maintaining the integrity of the endothelium through the release




of proangiogenic cytokines and growth factors (Kaplan and Jackson, 2011).

Occurrence of endothelial damage can cause increased activation of platelets which has an important role of appearing thrombus on the region and because of increased platelet activation, increased platelet consumption and thus, increased joining of new and big volume, more reactive platelet occurs (Ariöz et al., 2007).

Evaluation of platelet indices can be a useful screening test for early identification of preeclampsia as its estimation can be considered as early, economical and rapid procedures of assessment of severity of preeclamptic cases and have a significant impact on maternal and perinatal outcome (Vijava et al., 2014).

Plateletcrit (total platelet mass), which corresponds to the volume that platelets have in 100ml of total blood, is the product of platelet count and MPV (Freitas et al., 2013). It can be mentioned to be analogous to the hematocrit. PCT is the most physiologically relevant parameter in hemostasis and in regulation of hematopoiesis (Butkiewicz et al., 2006).





$$PCT \% = \frac{MPV*PLT*10^9/l}{10}$$

The aim of this study, therefore, to investigate the association between reduced PCT and preeclampsia even in women with normal platelet count (Dadhich et al., 2012; Han et al., 2014; Yang et al., 2014; Mondal et al., 2015) one large prospective study has been showed that PCT is significant predicator of development of preeclampsia (Yang et al., 2014).

The aim of the current study was to investigate the relationship between platelets count and platelet indices, and severity of PE.

#### Chapter 1

#### PLATELET PHYSIOLOGY

latelets are small anucleate cell fragments that circulate in blood playing crucial role in managing vascular integrity and regulating hemostasis. Platelets are also involved in the fundamental biological process of chronic inflammation associated with disease pathology. Platelet indices like mean platelets volume (MPV), platelets distributed width (PDW), and plateletcrit (PCT) are useful as cheap noninvasive biomarkers for assessing the diseased states. Dynamic platelets bear distinct morphology, where and dense granule are actively involved in secretion of molecules like GPIIb, IIIa, fibringen, vWf, catecholamines, serotonin, calcium, ATP, ADP, and so forth, which are involved in aggregation. Differential expressions of surface receptors like CD36, CD41, CD61 and so forth have also been quantitated in several diseases. Platelets activation and dysfunction have been implicated in many diseases (Ghoshal and Bhattacharyya, 2014).

The term thrombocyte (clot cell) came into use in the early 1900s and is sometimes used as a synonym for platelet; but not generally in the scientific literature, except as a root word for other terms related to platelets (e.g. thrombocytopenia meaning low platelets) (BMA, 2013). Platelets were discovered by Giulio Bizzozero in 1882 (Ribatti and Crivellato, 2007), but for many decades the dynamic and multifunctional nature of

platelets remained a field of interest only for biologists. Anucleate, discoid platelets are the smallest blood particles which unveil their dynamicity through their morphology. Primarily they are associated with hemostasis, which is to initiate blood coagulation. Although very dynamic, they usually prefer to remain in inactive state and get activated only when a blood vessel is damaged. But hemostasis or blood coagulation is not the sole function of platelets; rather it is employed in several multifunctional attributes monitoring the homeostasis of the body (Figure 1). Its high sensitivity to different disease states eventually assigned it to be one of the most accessible markers (Cerletti et al., 2012). Platelet reactivity for different disease pathogenesis is widely dependent upon biologically active markers like CD36, CD41, CD42a, CD42b, and CD61. These include some active surface receptors and platelet secretory products. Platelet tends to alter the expression and signaling of these markers in different disease diagnosis and prognosis, providing a huge field to explore disease progression (Ghoshal and Bhattacharyya, 2014).